Hackensack University Medical Center   Report issue

Academic/Hospital Phase 1 Phase 2 Phase 3 Phase 4
Founded: Hackensack NJ United States (1881)

Organization Overview

First Clinical Trial
2017
NCT03621722
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2022

Timeline

NOW
  • Now

Alternative names

Hackensack Meridian Health | Hackensack Meridian Health Corporation | Hackensack Meridian Health Network | Hackensack University Medical Centre | Jersey Shore Medical Center (Hackensack Meridian) | Joseph M.Sanzari Children's Hospital at Hackensack University Medical Center

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Pain (Phase 4)

Alopecia (Phase 2)

Alopecia Areata (Phase 2)

Amyotrophic Lateral Sclerosis (Phase 1)

Emergencies (Phase 4)

Extensively Drug-Resistant Tuberculosis (Phase 3)

Glioblastoma (Phase 1)

Glioma (Phase 2)

Graft vs Host Disease (Phase 2)

Infections (Phase 2)

Leukemia (Phase 2)

Leukemia, Lymphocytic, Chronic, B-Cell (Phase 2)

Leukemia, Lymphoid (Phase 2)

Melanoma (Phase 2)

Motor Neuron Disease (Phase 1)

Multiple Myeloma (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Pancreatic Diseases (Phase 3)

Pancreatic Neoplasms (Phase 3)

Sclerosis (Phase 1)

Tuberculosis (Phase 3)

Tuberculosis, Multidrug-Resistant (Phase 3)

Tuberculosis, Pulmonary (Phase 3)

Urinary Retention (Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 25
  • # of Trial APIs: 38